May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
A Phase II Double-Masked, Randomized, Parallel-Group Study to Assess the Safety and Efficacy of ALTY-0501 (Doxycycline 0.025% Ophthalmic Solution) in Dry Eye Patients Exposed to the Controlled Adverse Environment (CAE)
Author Affiliations & Notes
  • G. W. Ousler, III
    ORA Clinical Research & Development, North Andover, Massachusetts
  • D. Power
    Alacrity Biosciences, Laguna Hills, California
  • M. Schindelar
    ORA Clinical Research & Development, North Andover, Massachusetts
  • D. Welch
    ORA Clinical Research & Development, North Andover, Massachusetts
  • M. B. Abelson
    ORA Clinical Research & Development, North Andover, Massachusetts
    Harvard Medical School and Schepens Eye Research Institute, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  G.W. Ousler, ORA, E; D. Power, Alacrity Biosciences, E; M. Schindelar, ORA, E; D. Welch, ORA, E; M.B. Abelson, ORA, E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 102. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. W. Ousler, III, D. Power, M. Schindelar, D. Welch, M. B. Abelson; A Phase II Double-Masked, Randomized, Parallel-Group Study to Assess the Safety and Efficacy of ALTY-0501 (Doxycycline 0.025% Ophthalmic Solution) in Dry Eye Patients Exposed to the Controlled Adverse Environment (CAE). Invest. Ophthalmol. Vis. Sci. 2008;49(13):102. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : This study was designed to evaluate the safety and potential treatment benefit of ALTY-0501 for dry eye. The study used the controlled adverse environment (CAE), a clinical model which allows for standardized measurement of dry eye signs and symptoms in the investigation of therapeutic agents.

Methods: : One hundred sixty (160) patients were randomized to receive ALTY-0501 eye drops or its vehicle QID in a 56-day, double-masked, randomized, parallel-group Phase II trial. Dry eye patients were exposed to the CAE on day 1 and again at follow-up visits on days 28 and 56. Signs and symptoms of dry eye were assessed before, during, and after exposure to the CAE at each of these visits. Patients instilled study medications QID over 56 days, and recorded symptom severity measurements on a daily basis in a diary throughout the study.

Results: : The study did not reach statistical significance for the primary efficacy variables of change in central corneal fluorescein staining after CAE exposure and the symptom of ocular dryness at day 56. Patients who received active treatment however had statistically significantly lower fluorescein staining scores for the total cornea and conjunctiva as well as for the superior and nasal sub-regions following CAE exposure than those receiving vehicle (p < 0.05) on day 28. The active group also exhibited statistically significant benefits compared to vehicle in patient diary scores for symptoms of burning (p < 0.0001), stinging (p < 0.0001), and grittiness (p < 0.0001) over the study period.

Conclusions: : ALTY-0501 demonstrated statistically significant advantages over vehicle in managing the signs and symptoms of dry eye. The findings merit further study of the efficacy of ALTY-0501 in the treatment of dry eye.

Clinical Trial: : www.clinicaltrials.gov NCT00439400

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • cornea: tears/tear film/dry eye • cornea: clinical science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×